Sunday, November 22, 2026 · Davao City
DavaoNews
Sign in
33 days to Christmas!
Latest
Aboitiz Foods brings solar power and internet to five more remote Iligan schoolsUSeP instructor: weight-loss drug cannot fix spaces that shame plus-size womenCommentary: ASEAN must turn record investment into jobs and incomes, writer arguesTurn your bonus to savings: Smarter ways to use your 13th month payCebu Pacific opens its Pasay training academy to neurodivergent childrenEdge Davao columnist warns gossip can harm reputations and carry legal riskOVP says million-tree campaign not tied to Cale88's BOI tree-planting requirementDiesel may drop by up to P3 per liter, gasoline by P2.90 next weekPolice probe two separate shootings that left two dead in Davao CityHog raisers say pork supply enough for holidays, flag low Mindanao farmgate pricesAboitiz Foods brings solar power and internet to five more remote Iligan schoolsUSeP instructor: weight-loss drug cannot fix spaces that shame plus-size womenCommentary: ASEAN must turn record investment into jobs and incomes, writer arguesTurn your bonus to savings: Smarter ways to use your 13th month payCebu Pacific opens its Pasay training academy to neurodivergent childrenEdge Davao columnist warns gossip can harm reputations and carry legal riskOVP says million-tree campaign not tied to Cale88's BOI tree-planting requirementDiesel may drop by up to P3 per liter, gasoline by P2.90 next weekPolice probe two separate shootings that left two dead in Davao CityHog raisers say pork supply enough for holidays, flag low Mindanao farmgate prices
Opinion

USeP instructor: weight-loss drug cannot fix spaces that shame plus-size women

In a Mindanao Times column, Kethelle Sajonia argues that tirzepatide offers real health gains but that confidence should not depend on getting smaller.

DavaoNews Desk · based on reporting by Mindanao TimesSun, Nov 22, 1:08 PM
Photo: Mindanao Times

Kethelle I. Sajonia, a college instructor at the University of Southeastern Philippines (USeP) Mintal Campus in Davao City, argues in a column for Mindanao Times that the popular weight-loss medicine tirzepatide can change women's bodies but not the culture and public spaces that make plus-size Filipino women feel unwelcome.

Writing as a plus-size woman who studies how bodies move through public space, Sajonia acknowledges the drug's results. She cites the SURMOUNT-1 trial published in the New England Journal of Medicine, in which more than 2,500 adults were followed for 72 weeks; those on the highest dose lost about 21% of their body weight on average, compared with about 3% for the placebo group. She also notes that participants reported better quality of life, particularly in physical functioning.

Her concern, she writes, is why confidence so often comes only after a woman becomes smaller. Drawing on what she calls critical body proxemics, she points to narrow chairs in government offices, jeepney seats meant for "ten persons, five on each side," and relatives' comments about weight. When women lose weight, she argues, part of their newfound confidence is relief: "The room didn't learn to welcome her. She changed to fit the room." She cites research by Rebecca Pearl, Rebecca Puhl and colleagues linking internalised weight stigma to poorer health outcomes and avoidance of medical care.

Sajonia also raises cost. The registered pen is expensive and paid out of pocket, she writes, which has fuelled online sellers of cheaper "unbranded" or compounded tirzepatide. She notes that Mounjaro KwikPen is the only tirzepatide product approved by the FDA Philippines, that the agency has warned against unregistered products, and that the Philippine College of Physicians has cautioned that compounded versions have not undergone clinical trials and selling them may violate the Pharmacy Law.

Rather than blaming women who take that route, she calls for affordable legitimate treatment, obesity care through PhilHealth and public clinics, and independent Filipino-led research, noting that SURMOUNT-1 participants were around 70% white and that the SURMOUNT-4 trial found people who stopped the drug regained substantial weight. Citing DOST-FNRI data that obesity among Filipino adults aged 20 to 59 rose to 44.5% in 2025, she argues that women who choose the medicine with their doctors deserve support, while cities, clinics and families should make room for people of every size.

Why it matters for Davao

With DOST-FNRI reporting obesity among 44.5% of working-age Filipino adults, the column raises questions about safe access to weight-loss treatment and how inclusive everyday spaces such as jeepneys and offices are for Davao residents.

This article was written by the DavaoNews desk with AI assistance, using reporting by Mindanao Times. Facts come from the original report, which we credit and link below. Our editorial policy

Read the original at Mindanao Times

How does this story make you feel?

Be the first to respond

Share this story

Sign in to get a personal share link and earn community points when readers open it.

Discussion (0)

Sign in with Google to join the discussion.

Sign in to comment

No comments yet. Start the conversation.